Literature DB >> 12538490

Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

Soo Ok Lee1, Wei Lou, Min Hou, Fernando de Miguel, Lizabeth Gerber, Allen C Gao.   

Abstract

PURPOSE: Prostate cancer frequently progresses from an initial androgen dependence to androgen independence, rendering the only effective androgen ablation therapy useless. The mechanism underlying the androgen-independent progression is incompletely understood. Interleukin (IL)-6 has been implicated in this androgen-independent progression. In this study, we tested whether IL-6 induces androgen-independent growth both in vitro and in vivo. EXPERIMENTAL
DESIGN: IL-6 was expressed in androgen-sensitive LNCaP cells. The effects of IL-6 on androgen receptor activity was determined by Northern blots and gel shift assays. The effects of IL-6 on LNCaP cell growth were determined in vitro by MTT assay and in vivo.
RESULTS: IL-6 can enhance the growth of androgen-sensitive LNCaP cells in the androgen-deprived condition in vitro, which is accompanied by elevation of androgen-regulated prostate-specific antigen mRNA expression. IL-6 promotes androgen-sensitive LNCaP cell tumor growth in the castrated male mice. IL-6 enhances androgen receptor DNA binding activity and nuclear translocation. The androgen-independent phenotype induced by IL-6 in LNCaP cells is accompanied by significant activation of signal transducers and activators of transcription 3 and mitogen-activated protein kinase signal pathways.
CONCLUSIONS: These studies clearly provide experimental evidence that IL-6 initiates and/or enhances the transition of prostate cancer cells from an androgen-dependent to an androgen-independent phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538490

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  72 in total

1.  The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels.

Authors:  Yosra Bouraoui Mechergui; Awatef Ben Jemaa; Chekib Mezigh; Benito Fraile; Nawfel Ben Rais; Ricardo Paniagua; Mar Royuela; Ridha Oueslati
Journal:  Inflammation       Date:  2009-04-28       Impact factor: 4.092

Review 2.  Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.

Authors:  N G R Dayan Elshan; Matthew B Rettig; Michael E Jung
Journal:  Med Res Rev       Date:  2018-11-22       Impact factor: 12.944

3.  Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Soo Ok Lee; Xin Lin; Donald L Trump; Allen C Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

4.  The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.

Authors:  Awatef Ben Jemaa; Sataa Sallami; Dunia Ramarli; Marco Colombatti; Ridha Oueslati
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

5.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

Review 6.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

7.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

8.  Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Authors:  Nima Sharifi; Elaine M Hurt; Suneetha B Thomas; William L Farrar
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 9.  Molecular markers in prostate cancer. Part I: predicting lethality.

Authors:  Sachin Agrawal; William D Dunsmuir
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.